ACLX News and Press, Arcellx Inc. From 02/29/24

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference PR Newswire REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunot...

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights PR Newswire -- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in p...

2024-02-15 11:57:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following a hot year of M&A with biotech stocks , we’ll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between n...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2024-01-30 05:13:34 ET Summary Arcellx is focused on engineering safer and more accessible cell therapies for cancer patients and those with incurable diseases. The company's lead product candidate, CART-ddBCMA, has shown potential as a game-changing strategy for the treatment of ...

2024-01-16 13:51:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks , and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clamp...

2024-01-16 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead

2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...